Taken together, these data demonstrate that TM4SF1 may be a new therapeutic target for TM4SF1-expressing bladder cancers, including tumors with variant histology and those lacking NECTIN4 expression, and can be successfully targeted using CAR T cell therapy in a mouse xenograft model. This evidence concerns the gene NECTIN4 and urinary bladder cancer.